Dasatinib Reinitiation After Poststroke Thrombolysis Associated with Symptomatic Intracerebral Hemorrhage

• Published in: World neurosurgery 2019-05, Vol.125, p.383-386
• Main Authors: Hamilton, Robert A., Hathidara, Mausaminben, Shujaat, Syeda Dania, Strickland, Allison E., Bohnstedt, Bradley N., Ray, Bappaditya
• Format: Article
• Language: English
• Subjects: Acute ischemic stroke; Dasatinib; Symptomatic intracranial hemorrhage; Thrombolytic therapy; Tissue plasminogen activator
• ISSN: 1878-8750; 1878-8769
• DOI: 10.1016/j.wneu.2019.02.026

Dasatinib, a tyrosine kinase inhibitor commonly used in treatment of acute lymphoblastic leukemia and chronic myelogenous leukemia, is often associated with hemorrhagic complications. Safety of dasatinib after thrombolytic therapy in acute ischemic stroke is unknown. A 63-year-old man with multiple vascular risk factors and chronic myelogenous leukemia (in molecular remission) on dasatinib presented with signs and symptoms of right hemispheric stroke owing to acute intracranial internal carotid artery occlusion that was treated with intravenous thrombolysis and mechanical thrombectomy resulting in near-complete resolution of stroke symptoms. The patient developed clinical worsening (>24 hours of thrombolytic therapy) after receiving a second dose of dasatinib that was due to symptomatic intracerebral hemorrhage and necessitated decompressive hemicraniectomy. Routine coagulation profile was normal. The etiology of this hemorrhagic complication was likely secondary to primary platelet dysfunction due to dasatinib as reported in some recent in vitro and ex vivo studies. It is advisable to withhold dasatinib during the poststroke period owing to its associated risk of symptomatic intracerebral hemorrhage.